Abstract
August 2015 e33 analyser (Roche) respectively. Creatinine clearance was calculated using the Cockcroft-Gault equation. The Research Ethics Committee approved this study and subjects signed consent forms. Results: Serum netrin-1 levels were reduced following aspirin treatment (66.06 ± 22.98 pg/mL versus 79.79 ± 34.91 pg/mL at baseline; P = 0.0022). There was a linear association between the percentage change in netrin-1 and level of serum salicylate (r = 0.413, P = .0013). TXB2 levels fell in all subjects post-treatment, confirming adherence to treatment (32.99 ± 18.35 ng/mmol creatinine versus 143.7 ± 54.25 ng/mmol creatinine at baseline; P < 0.0001). Serum ICAM-1 and E-selectin levels were not modified by treatment. Creatinine clearance decreased following aspirin (103.2 ± 26.13 mL/min versus 110.5 ± 26.95 mL/min at baseline; P = 0.0011). Conclusion: This study demonstrates that serum netrin-1 is reduced following treatment with aspirin. The TXB2 measurements show effective platelet inhibition in the whole population. We observed no change in ICAM-1 or E-selectin levels suggestive of an effect on the vascular endothelial function. Netrin-1 is a known biomarker of renal impairment. We propose that the reduction in netrin-1 is secondary to drug-induced renal dysfunction, as evidenced by a decrease in creatinine clearance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
